EW vs BSX Stock Comparison: AI Score, Valuation, Performance and Upside
Edwards Lifesciences and Boston Scientific are both major medical device companies with strong positions in cardiovascular care, but Edwards Lifesciences maintains a focused structural heart franchise centered on transcatheter aortic valve replacement, while Boston Scientific offers a more diversified portfolio spanning electrophysiology, endoscopy, and urology alongside its cardiology business.
Edwards Lifesciences offers concentrated exposure to structural heart therapy leadership, while Boston Scientific offers diversified exposure across multiple medical device categories including a fast-growing electrophysiology franchise. Consider whether you prefer Edwards' focused structural heart bet or Boston Scientific's broader diversification.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want concentrated exposure to structural heart disease therapy leadership
- Believe transcatheter aortic valve replacement adoption has continued room to grow globally
- Value deep clinical expertise focused on a specific therapeutic area
- Are comfortable with revenue concentration risk in a single medical device category
- Prefer diversified exposure across cardiology, electrophysiology, endoscopy, and urology
- Believe the growing electrophysiology franchise offers a meaningful long-term growth driver
- Value broad commercial infrastructure supporting multiple device categories
- Want reduced reliance on any single product line for overall company growth
| Metric | EW | BSX |
|---|---|---|
| AI scorei | N/A | N/A |
| AI ranki | N/A | N/A |
| Latest closei | N/A | N/A |
| Metric | EW | BSX |
|---|---|---|
| Market capi | N/A | N/A |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | N/A |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | N/A | N/A |
| Analyst targeti | N/A | N/A |
| Target upsidei | N/A | N/A |
| Metric | EW | BSX |
|---|---|---|
| Revenue growthi | N/A | N/A |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | N/A |
| Operating margini | N/A | N/A |
| Profit margini | N/A | N/A |
| ROIC proxyi | N/A | N/A |
| Return on equityi | N/A | N/A |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | N/A |
| Dividend growth streaki | N/A | N/A |
| Betai | N/A | N/A |
| Debt/equityi | N/A | N/A |
| Current ratioi | N/A | N/A |
| Quick ratioi | N/A | N/A |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EW | BSX |
|---|---|---|---|
| 1Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 5Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A | |
| 10Y | Growthi | N/A | N/A |
| CAGRi | N/A | N/A | |
| Volatilityi | N/A | N/A | |
| Sharpe ratioi | N/A | N/A | |
| Sortino ratioi | N/A | N/A | |
| Max drawdowni | N/A | N/A | |
| Current drawdowni | N/A | N/A | |
| Avg drawdowni | N/A | N/A | |
| Ulcer Indexi | N/A | N/A | |
| Max daily dropi | N/A | N/A | |
| Max wkly dropi | N/A | N/A |
| Category | EW | BSX |
|---|---|---|
| Company | Edwards Lifesciences Corporation | Boston Scientific Corporation |
| Sector | Medical Devices | Medical Devices |
| Industry | N/A | N/A |
| Core business | A medical technology company focused on structural heart disease and critical care monitoring, best known for pioneering transcatheter aortic valve replacement therapy used to treat heart valve disease without open-heart surgery. | A diversified medical device company with a broad portfolio spanning cardiology, electrophysiology, endoscopy, and urology, including a growing electrophysiology franchise focused on treating irregular heart rhythms. |
| Investor focus | Transcatheter aortic valve replacement adoption growth and international expansion, structural heart pipeline progress, and competitive dynamics within the heart valve therapy market. | Electrophysiology franchise revenue growth, structural heart product pipeline progress, and overall diversification benefits across its multiple medical device business segments. |
- Pioneering position in transcatheter aortic valve replacement therapy established early leadership in a large, growing treatment category
- Focused structural heart portfolio allows deep clinical expertise and sustained research investment in a specific therapeutic area
- Critical care monitoring business provides diversification alongside its core structural heart franchise
- Diversified medical device portfolio across cardiology, electrophysiology, endoscopy, and urology reduces reliance on any single product category
- Growing electrophysiology franchise addresses a large and expanding market for irregular heart rhythm treatment
- Broad commercial infrastructure and physician relationships support the launch and adoption of new devices across categories
- Faces increasing competition in transcatheter aortic valve replacement from other large medical device manufacturers
- Revenue concentration in structural heart therapies creates exposure to procedure volume and reimbursement changes
- New pipeline therapies must continue to gain regulatory approval and clinical adoption to sustain growth
- Operates in numerous competitive medical device categories, requiring sustained investment to maintain share across each
- Growth in newer categories like electrophysiology must continue to offset any maturity in legacy device lines
- Faces the typical regulatory and product recall risks inherent in operating a broad medical device portfolio
Compare more than two at a time
This page is a fixed writeup on EW and BSX. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside EW and BSX, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.